Dawn of Targeted Therapy Using Claudin18.2 for Gastric Cancer

LI Hao; YE Xianhui; ZHOU Junjie; LI Xiaofen

doi:10.3971/j.issn.1000-8578.2023.23.0164

Zhongliu Fangzhi Yanjiu (Oct 2023)

Dawn of Targeted Therapy Using Claudin18.2 for Gastric Cancer

LI Hao,
YE Xianhui,
ZHOU Junjie,
LI Xiaofen

Affiliations

LI Hao: Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China
YE Xianhui: Colorectal Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China
ZHOU Junjie: Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China
LI Xiaofen: Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China

DOI: https://doi.org/10.3971/j.issn.1000-8578.2023.23.0164
Journal volume & issue: Vol. 50, no. 10
pp. 1022 – 1028

Abstract

Read online

In recent years, significant advancements in molecular biology have paved the way for novel targeted therapeutic strategies for gastric cancer treatment. Claudin18, which is an important structural protein involved in tight junctions between cells, and its subtype Claudin18.2 (CLDN18.2), which is specifically expressed in differentiated gastric epithelial cells, have emerged as novel therapeutic targets for patients with gastric cancer. This article aims to systematically review the latest developments in CLDN18.2 research in the fields of basic and clinical gastric cancer studies to provide a reference for clinical practice.

Published in Zhongliu Fangzhi Yanjiu

ISSN: 1000-8578 (Print)
Publisher: Magazine House of Cancer Research on Prevention and Treatment
Country of publisher: China
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.zlfzyj.com

About the journal

Abstract

Keywords